Dr. Roman Perez-Soler, from Albert Einstein College of Medicine, on the Future of Lung Cancer Therapies
OncLive TV
Dr. Sundar Jagannath, from Mount Sinai Medical Center, Discusses the VANTAGE Trials
Advertisement
Dr. Freya Schnabel from NYU School of Medicine Discusses the DCIS Recurrence Score
Dr. Harold Harvey from Penn State Hershey Cancer Institute Discusses Preventing Breast Cancer
Dr. Stephen Ansell from the Mayo Clinic in Minnesota Describes Waldenstrom Macroglobulinemia Symptoms
Dr. Chandra Belani from Penn State Hershey Cancer Institute Discusses Driver Mutations in NSCLC
Advertisement
Dr. Sridhar Ramaswamy from the Massachusetts General Hospital Cancer Center Discusses Tumor Heterogeneity
Dr. Jose Baselga from Massachusetts General Hospital Discusses the BOLERO Breast Cancer Trials
Dr. William Wierda, from MD Anderson Cancer Center, on Diagnosing Chronic Lymphocytic Leukemia
Dr. Ruben Mesa from the Mayo Clinic in Arizona Discusses JAK Inhibitors for Myelofibrosis
Dr. Michael Birrer from Massachusetts General Hospital Cancer Center on the Ovarian Cancer Avastin OS Benefit
Dr. Leonard Gomella from the Jefferson Kimmel Cancer Center on the Cost of the Immunotherapy Sipuleucel-T
Dr. Sundar Jagannath from the Tisch Cancer Institute Discusses HDAC Inhibitors for Multiple Myeloma
Dr. Lawrence Solin from Einstein Medical Center on Personalizing Treatment With the DCIS Score
Dr. Daniel Petrylak, from the Herbert Irving Comprehensive Cancer Center, Discusses the Isotope Radium-223
Dr. Howard Burris from Sarah Cannon Research Institute Discusses Recurrence Scores Predicting pCR
Dr. Edith Perez from the Mayo Clinic Cancer Center Discusses Optimizing Adjuvant Therapy
Dr. Freya Schnabel from NYU School of Medicine on Predicting Breast Cancer by Atypia Type
Dr. Harold Harvey from Penn State Hershey Cancer Institute on Aromatase Inhibitor Treatment Duration
Dr. Brian Leyland-Jones from Winship Cancer Institute Discusses Genome Sequencing
Dr. Kenneth Bloom, from Chief Medical Officer at Clarient, Explains Situations Requiring HER2 Retesting
Dr. Leonard Gomella, from Jefferson Kimmel Cancer Center, Discusses the NeoACT Sipuleucel-T Study
Dr. Roman Perez-Soler, from Montefiore Medical Center, on Treatment Options for NSCLC
Dr. Sridhar Ramaswamy, from Massachusetts General Hospital Cancer Center, on Dormant Tumor Cells and Resistance
Dr. Paul Hamlin, from Memorial Sloan-Kettering Cancer Center, Discusses Integrating Brentuximab Vedotin
Dr. Barry Rosenbloom, from the Comprehensive Gaucher Treatment Center, on Gaucher Disease Diagnosis Challenges
Dr. James Berenson, from the Institute for Myeloma & Bone Cancer Research, on Zometa as the Gold Standard for MM
Dr. Howard Burris, from the Sarah Cannon Research Institute, Discusses the Stratification of Clinical Trials
Dr. Edith Perez, from the Mayo Clinic Cancer Center, Describes Retesting Recurrent Breast Cancer
Dr. Jose Baselga, from Massachusetts General Hospital, Describes the Basis Behind the BOLERO-2 Trial
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
3
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
4
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
5